Open Orphan #ORPH – Pre-Admission Announcement for Euronext Growth Markets

Pre-Admission Announcement Euronext Growth Schedule 1 Announcement to be made by the Applicant prior to admission in accordance with the Euronext Growth Markets Rule Book All Applicants must complete the following Company name   Open Orphan plc (“Open Orphan” or the “Company”, and together with its subsidiaries the “Group”)   Company registered address and if different, […]

Open Orphan #ORPH – New 3 Year Contract with major Pharmaceutical Company

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a new 3-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees significant annual revenue with work under the contract to commence this month. This contract sees Venn Life Sciences […]

Open Orphan #ORPH – hVIVO #HVO offer now unconditional as to acceptances

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF ANY SUCH JURISDICTION 31 December 2019 Recommended All Equity Offer for HVIVO PLC (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”) First Closing […]

Open Orphan #ORPH – New Contract with SFA Therapeutics

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, USA (“SFA Therapeutics”). This contract sees Venn Life Sciences (“Venn”), part of Open Orphan plc, provide SFA Therapeutics with assistance in the filing of a European Medicines Agency […]

Open Orphan #ORPH – Recommended All-Equity Offer for hVIVO #HVO

  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISION IN RELATION TO HVIVO SHARES OR NEW OPEN ORPHAN SHARES EXCEPT ON […]

Open Orphan’s (ORPH) Maurice Treacy Hosts Value the Markets Webinar

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time). Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the […]